Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
Antonio Ciudad,1 Ernie Anand,2 Lovisa Berggren,3 Marta Casillas,4 Alexander Schacht,3 Elena Perrin5 1Department of Clinical Research and Development, Eli Lilly & Co, Madrid, Spain; 2Neuroscience Medical Affairs – EU, Lilly Research Centre, Windlesham, Surrey, UK; 3Global Statistica...
Enregistré dans:
Auteurs principaux: | Ciudad A, An, E, Berggren L, Casillas M, Schacht A, Perrin E |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/475b8a7edd4b4ba3b86b86d9089252d9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Long-acting injectable antipsychotics: focus on olanzapine pamoate
par: JP Lindenmayer
Publié: (2010) -
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
par: An, et autres
Publié: (2015) -
Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
par: Rosaria Di Lorenzo, et autres
Publié: (2010) -
Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
par: Anand E, et autres
Publié: (2016) -
Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
par: Katagiri H, et autres
Publié: (2018)